Peppa, M.; Manta, A.; Mavroeidi, I.; Asimakopoulou, A.; Syrigos, A.; Nastos, C.; Pikoulis, E.; Kollias, A.
Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus. Pharmaceutics 2023, 15, 2526.
https://doi.org/10.3390/pharmaceutics15112526
AMA Style
Peppa M, Manta A, Mavroeidi I, Asimakopoulou A, Syrigos A, Nastos C, Pikoulis E, Kollias A.
Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus. Pharmaceutics. 2023; 15(11):2526.
https://doi.org/10.3390/pharmaceutics15112526
Chicago/Turabian Style
Peppa, Melpomeni, Aspasia Manta, Ioanna Mavroeidi, Athina Asimakopoulou, Alexandros Syrigos, Constantinos Nastos, Emmanouil Pikoulis, and Anastasios Kollias.
2023. "Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus" Pharmaceutics 15, no. 11: 2526.
https://doi.org/10.3390/pharmaceutics15112526
APA Style
Peppa, M., Manta, A., Mavroeidi, I., Asimakopoulou, A., Syrigos, A., Nastos, C., Pikoulis, E., & Kollias, A.
(2023). Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus. Pharmaceutics, 15(11), 2526.
https://doi.org/10.3390/pharmaceutics15112526
